Erzotabart

埃泽妥拜单抗

Report date: 2025/09/17 20:01:18

Base Information

Drug NameErzotabart

Drug Alias NameHexaBody®-CD38GEN-3014

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement activation stimulantsImmunomodulators +[4]

TargetsLymphocyte differentiation antigen CD38

Therapy Area/IndicationsMultiple MyelomaLymphoma, Large B-Cell, DiffuseLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBosnia and HerzegovinaUnited States +[19]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGenmab A/S

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenmab A/S Johnson & Johnson

Active IndicationsN/A

Inactive IndicationsMultiple MyelomaLymphoma, Large B-Cell, DiffuseLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A